Literature DB >> 2877284

Seven-year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal).

P Coursaget, B Yvonnet, J Chotard, M Sarr, P Vincelot, R N'doye, I Diop-Mar, J P Chiron.   

Abstract

A booster dose of hepatitis B vaccine was given to 143 children in whom hepatitis B had not developed 1 year after initial vaccination. Over the next six years the incidence of hepatitis B in this group was 1.5% per year compared with 11.5% per year in a similar group of unvaccinated children. In the first 4 years the protective efficacy of the vaccine was 100%, but during the 5th and 6th years it fell to 67%. For maximum protection a second booster is needed, 5 years after the first.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2877284     DOI: 10.1016/s0140-6736(86)90543-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  18 in total

1.  Can HB vaccine yield a booster effect on individuals with positive serum anti-HBs and anti-HBc markers?

Authors:  Ru-Xiang Wang; Ying Guo; Chang-Hong Yang; Yu Song; Juan Chen; Fu-Sheng Pang; Shao-Ping Lei; Xiao-Ming Jia; Jin-Ying Wen; Christina Y Shi
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

2.  Universal hepatitis B vaccination: the economics of prevention.

Authors:  M D Krahn; A S Detsky
Journal:  CMAJ       Date:  1992-01-01       Impact factor: 8.262

3.  Hepatitis B in Canada: the case for universal vaccination. Infectious Diseases and Immunization Committee, Canadian Paediatric Society.

Authors: 
Journal:  CMAJ       Date:  1992-01-01       Impact factor: 8.262

4.  A 12-year cohort study on the efficacy of plasma-derived hepatitis B vaccine in rural newborns.

Authors:  Hong-Bin Liu; Zong-Da Meng; Jing-Chen Ma; Chang-Quan Han; Ying-Lin Zhang; Zhan-Chun Xing; Yu-Wei Zhang; Yu-Zhong Liu; Hui-Lin Cao
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

5.  Duration of hepatitis B antibody response in children immunised with hepatitis B and compulsory vaccines.

Authors:  S Li Volti; G Giammanco-Bilancia; G Giammanco; F Mollica
Journal:  Eur J Epidemiol       Date:  1995-04       Impact factor: 8.082

6.  Statement on immunizing agents for the prevention of hepatitis.

Authors: 
Journal:  CMAJ       Date:  1987-08-15       Impact factor: 8.262

7.  Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas.

Authors:  W J Edmunds; G F Medley; D J Nokes; C J O'Callaghan; H C Whittle; A J Hall
Journal:  Epidemiol Infect       Date:  1996-10       Impact factor: 2.451

8.  Long-term immunogenicity and efficacy of a reduced dose of plasma-based hepatitis B vaccine in young adults.

Authors:  K T Goh; C J Oon; B H Heng; G K Lim
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

Review 9.  The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa.

Authors:  C F Kiire
Journal:  Gut       Date:  1996       Impact factor: 23.059

Review 10.  Update on diagnosis, management, and prevention of hepatitis B virus infection.

Authors:  F J Mahoney
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.